Anavex Life Sciences (NASDAQ:AVXL) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Anavex Life Sciences (NASDAQ:AVXL) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03, Zacks reports.

Anavex Life Sciences Trading Down 0.6 %

NASDAQ AVXL traded down $0.05 on Wednesday, reaching $8.24. The company’s stock had a trading volume of 659,999 shares, compared to its average volume of 1,579,105. The business has a 50-day moving average price of $9.93 and a 200 day moving average price of $7.69. The firm has a market cap of $698.75 million, a PE ratio of -15.93 and a beta of 0.69. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $14.44.

Analyst Upgrades and Downgrades

AVXL has been the subject of a number of research analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $42.00 price target on shares of Anavex Life Sciences in a report on Tuesday, January 28th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.